Profile data is unavailable for this security.
About the company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
- Revenue in CHF (TTM)184.69m
- Net income in CHF-374.06m
- Incorporated2017
- Employees1.36k
- LocationIdorsia LtdHegenheimermattweg 91ALLSCHWIL 4123SwitzerlandCHE
- Websitehttps://www.idorsia.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Partners AG | 7.04m | -61.98m | 122.75m | 168.00 | -- | 0.6285 | -- | 17.44 | -1.89 | -1.89 | 0.2147 | 5.37 | 0.0306 | -- | 4.74 | 41,892.86 | -26.91 | -11.83 | -28.90 | -14.69 | -- | 99.28 | -880.70 | -45.30 | -- | -70.97 | 0.0203 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Santhera Pharmaceuticals Holding AG | 5.16m | -64.69m | 124.36m | 46.00 | -- | -- | -- | 24.09 | -27.26 | -27.26 | 1.35 | -4.65 | 0.0723 | 34.23 | 3.54 | 112,217.40 | -90.56 | -54.38 | -250.35 | -75.34 | 29.39 | 78.16 | -1,253.16 | -209.10 | 0.0778 | -2.29 | -- | -- | 568.53 | -20.10 | -27.87 | -- | 23.14 | -- |
| Newron Pharmaceuticals SpA | 8.80m | -15.76m | 135.46m | 23.00 | -- | -- | -- | 15.39 | -0.8834 | -0.8834 | 0.4932 | -1.63 | 0.2873 | -- | 4.57 | 382,638.80 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Xlife Sciences AG | 1.00m | 16.13m | 195.05m | 19.00 | 27.10 | 0.8054 | 7.32 | 194.37 | 1.26 | 1.26 | 0.1368 | 42.47 | 0.0021 | -- | 1.68 | 52,815.79 | 2.25 | -- | 2.88 | -- | 30.17 | -- | 1,062.47 | -- | -- | -- | 0.1437 | -- | 27.53 | -- | -73.21 | -- | -- | -- |
| Kuros Biosciences AG | 33.56m | -13.73m | 282.76m | 80.00 | -- | 4.97 | -- | 8.42 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 184.69m | -374.06m | 343.70m | 1.36k | -- | -- | -- | 1.86 | -2.11 | -2.11 | 1.04 | -4.65 | 0.2201 | 0.2374 | 62.89 | 135,698.00 | -44.59 | -43.40 | -62.30 | -48.06 | 94.92 | -- | -202.54 | -966.50 | 1.02 | -26.39 | 3.77 | -- | 174.70 | -9.29 | -30.46 | -- | 28.72 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 546.33m | 147.00 | 47.58 | -- | 45.33 | 3.47 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 315.66m | -49.98m | 956.65m | 1.20k | -- | 2.57 | -- | 3.03 | -1.51 | -1.51 | 9.53 | 11.24 | 0.5137 | 2.31 | 5.08 | 262,612.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 93.99m | 1.11m | 1.24bn | 325.00 | 1,021.55 | 2.74 | 81.77 | 13.20 | 0.0692 | 0.0692 | 5.83 | 25.83 | 0.1473 | 3.06 | 2.88 | 289,187.10 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
Data as of Apr 18 2024. Currency figures normalised to Idorsia Ltd's reporting currency: Swiss Franc CHF
16.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 5.81m | 3.08% |
| Lazard Asset Management Ltd.as of 13 Jan 2023 | 5.32m | 2.82% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 4.42m | 2.35% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 4.38m | 2.32% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.17m | 1.68% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 2.61m | 1.38% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 2.27m | 1.20% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 1.71m | 0.91% |
| Rossier, Mari & Associates AGas of 31 Dec 2023 | 970.00k | 0.51% |
| Banque Cantonale de Gen�ve (Investment Management)as of 15 Sep 2023 | 858.16k | 0.46% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
